Wolfgang Hackl: Revolutionizing Cancer Treatment with Precision and Purpose
Cancer is notoriously complex. It doesn’t follow a predictable playbook, and even with the most advanced diagnostics and innovative drugs, treatments can miss the mark. For many patients, a tumor may qualify for a certain therapy, but that doesn’t guarantee the treatment will work. This disconnect highlights two major challenges in oncology today: overtreatment and undertreatment. Beyond inflating healthcare costs, they put patients at risk of ineffective care and unnecessary side effects. Enter PredictionStar™ —a bold solution aimed at closing that gap. Instead of relying solely on traditional markers of treatment eligibility and intensity, PredictionStar™ factors in how tumors are likely to respond, offering actionable, personalized insights. And at the helm of this transformation is Wolfgang Hackl , CEO of OncoGenomX . From Oncology Expert to Visionary Leader Wolfgang Hackl’s career spans over 20 years in oncology, with deep expertise in cancer drug development. His track r...